Fig. 4From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysisForest plots of RR of grade 3–4 AEs (a), drug discontinuations (b), drug reductions (c) and drug discontinuations due to the serious AEs (d) associated with pazopanib versus sunitinibBack to article page